Generali Asset Management SPA SGR Buys New Position in The Clorox Company (NYSE:CLX)

Generali Asset Management SPA SGR acquired a new position in The Clorox Company (NYSE:CLX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,788 shares of the company's stock, valued at approximately $940,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of CLX. Ilex Capital Partners UK LLP increased its stake in Clorox by 512.7% in the 3rd quarter. Ilex Capital Partners UK LLP now owns 542,110 shares of the company's stock valued at $88,315,000 after purchasing an additional 453,624 shares in the last quarter. Amundi increased its position in shares of Clorox by 42.6% in the fourth quarter. Amundi now owns 1,032,283 shares of the company's stock valued at $165,816,000 after buying an additional 308,234 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Clorox by 302.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 353,367 shares of the company's stock worth $57,390,000 after buying an additional 265,455 shares during the last quarter. State Street Corp boosted its position in shares of Clorox by 3.1% in the 3rd quarter. State Street Corp now owns 8,182,109 shares of the company's stock worth $1,332,947,000 after buying an additional 245,525 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Clorox in the 4th quarter worth about $37,935,000. Institutional investors and hedge funds own 78.53% of the company's stock.

Clorox Trading Down 1.5 %

NYSE:CLX traded down $2.11 during trading hours on Tuesday, reaching $141.80. 1,556,338 shares of the company were exchanged, compared to its average volume of 1,210,271. The firm has a market cap of $17.47 billion, a price-to-earnings ratio of 38.74, a PEG ratio of 2.62 and a beta of 0.45. The stock has a 50 day simple moving average of $152.57 and a 200 day simple moving average of $159.59. The Clorox Company has a 52-week low of $127.60 and a 52-week high of $171.37. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60.

Remove Ads

Clorox (NYSE:CLX - Get Free Report) last issued its earnings results on Monday, February 3rd. The company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.16. Clorox had a return on equity of 316.87% and a net margin of 6.38%. During the same period last year, the company posted $2.16 EPS. As a group, analysts predict that The Clorox Company will post 7.15 EPS for the current year.

Clorox Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Wednesday, April 23rd will be paid a dividend of $1.22 per share. The ex-dividend date is Wednesday, April 23rd. This represents a $4.88 annualized dividend and a yield of 3.44%. Clorox's dividend payout ratio is currently 133.33%.

Analyst Upgrades and Downgrades

CLX has been the subject of a number of research reports. JPMorgan Chase & Co. lifted their target price on shares of Clorox from $171.00 to $173.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Wells Fargo & Company lifted their price objective on Clorox from $157.00 to $161.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 4th. Evercore ISI increased their target price on Clorox from $145.00 to $155.00 in a report on Tuesday, February 4th. DA Davidson cut their price target on Clorox from $171.00 to $169.00 and set a "neutral" rating for the company in a report on Wednesday, February 5th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and set a $150.00 price objective on shares of Clorox in a research note on Thursday, January 30th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $159.62.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.